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When faced with acute neurological presentations in a patient with COVID-19, 
how confident can one be that SARS-CoV2 is causal?
Introduction
Clinicians are increasingly recog-
nising neurological presentations occur 
in some patients.1 A case series from 
Wuhan described associated neurological 
syndromes (eg, ‘dizziness’ and ‘impaired 
consciousness’), but with little detail 
regarding symptomatology, and cerebro-
spinal fluid (CSF) and neuroimaging find-
ings.2 The extent to which these disorders 
were caused by the virus per se, rather 
than being complications of critical illness, 
unmasking of degenerative disease, or 
iatrogenic effects of repurposed medica-
tions is not clear.
Numerous case reports have since 
emerged and, at the time of writing, 
published cases include encephalopathy,3 
encephalitis,4 Guillain- Barré syndrome 
(GBS)5 and stroke.6 In most of these cases, 
the virus has been identified in respi-
ratory samples, and in a small number 
in CSF. So far, the reporting of clinical 
features has been extremely variable, for 
example, several cases have claimed to 
report encephalitis without clear evidence 
of central nervous system (CNS) inflam-
mation, which would not meet established 
definitions of the disease.7
Whether severe acute respiratory 
syndrome coronavirus 2 (SARS- CoV2) 
is associated with neurological manifes-
tations is of critical importance as this 
may result in substantial morbidity and 
mortality.
Defining causality
It is crucial that neurologists and neuro-
psychiatrists apply a systematic strategy to 
determine whether there is evidence that 
SARS- CoV2 is causing these manifesta-
tions, whether they are a consequence of 
severe systemic disease alone, or simply 
coincidence. In 1965, Hill proposed 
criteria on which to build an argument for 
disease causation, which can be applied to 
COVID-19.8
What is the strength of the associ-
ation? So far, it appears fairly weak. 
>2.5 million people have been infected 
with SARS- CoV2 and to date (to the 
authors’ knowledge) there have been only 
93 published cases of neurological mani-
festations (about 5/100 000). However, 
reported cases are an underestimate of the 
real incidence, and this underscores the 
need for proper epidemiological study.
What is the consistency of the associ-
ation? So far, there have been published 
reports of neurological manifestations 
across the globe, including from China, 
Japan, Italy, France, the USA and the 
UK. Although the numbers are low, these 
are not isolated incidences and have 
occurred throughout the evolution of the 
pandemic.
To what extent is the relationship 
specific? The range of neurological 
manifestations reported in association 
with SARS- CoV2 is wide, from the CNS 
through to peripheral nerves. However, 
in previous pandemics, similar central and 
peripheral associations have been well 
recognised.9
What can temporality tell us about the 
association? The delay between infection 
and the neurological presentation may 
give a clue to mechanisms. Direct CNS 
infection might be expected to be contem-
poraneous with, or shortly after, fever 
and respiratory symptoms. Parainfectious 
disease, owing to innate immune responses, 
such as acute necrotising encephalopathy, 
usually occurs in the days following infec-
tion. Post- infectious syndromes, due to 
adaptive immune responses, such as GBS, 
are typically in the few weeks following 
infection. In most reported cases, respira-
tory disease has occurred a few days prior 
to the onset of the neurological syndrome 
although significant delays between a 
neurological presentation and COVID-19 
diagnosis in some raise the possibility of 
nosocomial infection.
Hill asks us to look for a biological 
gradient. In general, those with neuro-
logical manifestations have had severe 
COVID-19 respiratory disease suggesting 
the possibility that higher viral loads and/
or more fulminant inflammatory responses 
may be accountable for both.
Is there biological plausibility? Many 
human viruses can enter the CNS and 
some coronaviruses exhibit neurotro-
pism in animal models.10 The syndromes 
described so far could plausibly be related 
to primary infection with SARS- CoV2, 
although improved understanding of host 
responses is needed.
Hill asks us to consider the coher-
ence of the evidence. Perhaps our best 
sources of coherent data are the SARS 
and Middle East respiratory syndrome 
(MERS) epidemics: coronaviruses with 
about 80% and 50% homology to 
SARS- CoV2, respectively. Neurological 
syndromes were reported in association 
with both, including acute disseminated 
encephalomyelitis- like presentations with 
MERS and encephalopathy/encephalitis 
with SARS.11
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Is there any possibility of experimental 
evidence? The ideal investigational vehicle 
would be a case control study, but this 
presents design challenges as exposure 
is high and we do not yet have validated 
widespread antibody testing to ascertain 
seroprevalence.
Can we learn by analogy with other 
similar scenarios? Other respiratory 
viruses, most notably influenza, are well- 
established triggers of CNS damage. 
During the H1N1 pandemic, neurological 
syndromes were well described, including 
acute necrotising encephalopathy bearing 
striking resemblance to the case recently 
described with COVID-19.9 So, the emer-
gence of neurological disorders associated 
with pandemic viral infections is less the 
exception, and more the norm.
Conclusions
As always, our evidence must be founded 
on clear and systematic assessment of the 
clinical syndromes, supported by well- 
designed laboratory studies. Cases must 
be reported in line with clear clinical case 
definitions, both systematically and trans-
parently, and with honesty about negative 
or missing results.
These aims are best served by standardi-
sation and centralisation of case reporting, 
which calls for a truly collaborative 
approach between neurologists, neuropsy-
chiatrists and allied colleagues.
To address this, we have established the 
CoroNerve Studies Group as a collabora-
tion between professional bodies in the UK 
( CoroNerve. com), and similar studies are 
underway in other countries. However, 
a joined- up international approach is 
necessary. To begin this process, a compli-
mentary initiative, the COVID- Neuro 
Network, through Brain Infections Global, 
is supporting collaboration among several 
lower and middle- income countries.
We all must learn the lessons from 
previous pandemics, and the principles of 
Bradford Hill if we are to translate these 
rapidly growing datasets into meaningful 
advances in our understanding of the 
neurological complications of COVID-19.
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